Vantage Financial Partners Ltd. Inc. decreased its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 13.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,000 shares of the biotechnology company’s stock after selling 304 shares during the period. Vantage Financial Partners Ltd. Inc.’s holdings in Biogen were worth $638,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. SeaCrest Wealth Management LLC purchased a new stake in Biogen during the fourth quarter valued at about $504,000. Cambridge Investment Research Advisors Inc. lifted its stake in Biogen by 9.6% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 5,948 shares of the biotechnology company’s stock valued at $1,862,000 after buying an additional 520 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Biogen by 151.3% during the third quarter. Cubist Systematic Strategies LLC now owns 10,646 shares of the biotechnology company’s stock valued at $3,333,000 after buying an additional 6,409 shares in the last quarter. CHICAGO TRUST Co NA purchased a new stake in Biogen during the fourth quarter valued at about $740,000. Finally, Beech Hill Advisors Inc. lifted its stake in Biogen by 35.2% during the fourth quarter. Beech Hill Advisors Inc. now owns 1,987 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 517 shares in the last quarter. Institutional investors own 89.20% of the company’s stock.
In related news, CEO Michel Vounatsos purchased 780 shares of the stock in a transaction on Friday, December 29th. The shares were bought at an average price of $320.55 per share, for a total transaction of $250,029.00. Following the completion of the acquisition, the chief executive officer now directly owns 4,879 shares in the company, valued at approximately $1,563,963.45. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Alexander J. Denner purchased 30,000 shares of the stock in a transaction on Wednesday, November 29th. The shares were bought at an average price of $317.36 per share, for a total transaction of $9,520,800.00. Following the acquisition, the director now owns 10,029 shares of the company’s stock, valued at $3,182,803.44. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 31,560 shares of company stock worth $10,020,858. Corporate insiders own 0.25% of the company’s stock.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the consensus estimate of $5.44 by ($0.18). The business had revenue of $3.31 billion for the quarter, compared to the consensus estimate of $3.08 billion. Biogen had a net margin of 20.69% and a return on equity of 38.32%. Biogen’s revenue was up 15.1% compared to the same quarter last year. During the same period in the previous year, the business posted $5.04 EPS. equities analysts expect that Biogen Inc will post 24.88 EPS for the current year.
A number of analysts have commented on the stock. SunTrust Banks reaffirmed a “buy” rating and set a $354.00 price objective on shares of Biogen in a research note on Tuesday, October 24th. BMO Capital Markets reaffirmed a “buy” rating on shares of Biogen in a research note on Thursday, January 25th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Biogen in a research note on Thursday, February 8th. Argus lowered shares of Biogen from a “buy” rating to a “hold” rating in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $340.00 price target on shares of Biogen in a research report on Wednesday, October 25th. Ten investment analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $368.99.
TRADEMARK VIOLATION WARNING: “Vantage Financial Partners Ltd. Inc. Trims Stake in Biogen Inc (BIIB)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://stocknewstimes.com/2018/02/20/vantage-financial-partners-ltd-inc-trims-stake-in-biogen-inc-biib.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.